stanford synchrotron radiation lightsource science summary january 2011 potential anti cancer drug has novel mechanism of action stanford synchrotron radiation lightsource an office of science user facility quick facts 1 nobel prize winner 3 gev spear3 accelerator 30 experimental stations 300 institutions participating over 2000 scientists science at ssrl science highlights scientific techniques spear3 parameters publications beam lines contact us 2575 sand hill road menlo park ca 94025 usa 650 926 4000 map contact us home potential anti cancer drug has novel mechanism of action ssrl science summary 2011 raven hanna anticancer drug cancer diffraction dna medical applications bl11 1 cisplatin a platinum based anti cancer drug is a widely used and effective cancer chemotherapy drug it slows the growth of cancer cells by inhibiting transcription through dna modification creating chemical links that serve as a roadblock as the polymerase attempts to transcribe the dna into rna since cancer cells can develop resistance to cisplatin and related drugs researchers are interested in finding alternative treatments with different targets or mechanisms of action pyriplatin shows promise because as one member of a potentially larger class of such candidates it remains active in cisplatin resistant cells and has different chemical and biological properties whereas most chemically modified dnas affect transcription at the site of alteration dna modified by pyriplatin can be transcribed through the altered base but cannot continue further figure 1 rna pol ii stalled by a monofunctional pyriplatin dna adduct a team of researchers led by prof stephen j lippard of mit and dong wang at ucsd used ssrl beam line 11 1 to solve crystal structures of the rna pol ii transcription complexes stalled by a pyriplatin modification in a dna template they found that polymerase induced structural perturbations of the dna allow the pyriplatin modified nucleotide to be transcribed but prevent the next dna base from swinging into the active site of polymerase pyriplatin thus stops pol ii from moving down the dna template in a transcription stalling mechanism that is significantly different from that achieved by cisplatin modified dna the mechanism revealed by this study will allow further development of different and more potent anti cancer drugs this work was published in the may 25 2010 issue of the proceedings of the national academy of sciences publication dong wang guangyu zhu xuhui huang and stephen j lippard x ray structure and mechanism of rna polymerase ii stalled at an antineoplastic monofunctional platinum dna adduct pnas 107 9584 9589 2010 related links full scientific highlight contacts d wang s lippard login to post comments share printer friendly version post to twitter send to friend send to friend ssrl is supported by the department of energy office of basic energy sciences the ssrl structural molecular biology program is supported by the department of energy office of biological and environmental research and by the national institutes of health national center for research resources biomedical technology program and the national institute of general medical sciences the stanford synchrotron radiation lightsource is a directorate of slac national accelerator laboratory which is operated by stanford university for the department of energy stay connected twitter flickr youtube this site rss other news sources slac today ssrl headlines symmetry magazine lightsources org interactions org ilc newsline spires slac national accelerator laboratory slac national accelerator laboratory menlo park ca operated by stanford university for the us department of energy office of science content owner cathy knotts privacy notice security notice and terms of use doe stanford university
